Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 70.00p 70.00p 70.50p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 51.00

Silence Therapeutics Share Discussion Threads

Showing 50451 to 50474 of 50600 messages
Chat Pages: 2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  Older
DateSubjectAuthorDiscuss
10/12/2018
11:27
Peel Hunt comment H/T FT Alphaville We recognise that new management has never oversold the value of litigation (and we risk adjusted in our SOTP model) but that this outcome – whilst good news in putting ongoing risk and litigation cost behind us – is different to previous management’s communication of potential and our assumptions in the model (including £10m milestone and estimated royalties of 2-5%). This is validation of Silence’s expertise in the RNAi chemistry. New management is much more focused on pipeline and expects to build this out in the near future and is well capitalised for this (PHe 2018E of c£37m cash prior to adjusting for the milestones/todays news). Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products (whether commercialised by Alnylam, a collaborator or a licensee). Under this agreement, all ongoing court proceedings will now be dismissed. We will review with new management and temporarily move to U/R – we will update our model in due course, in order to assess new management’s perspective on timelines and indications now that litigation is out of the way. Future news flow – with the sensitivities of litigation now behind us, the company will now be able to focus on applying its RNAi expertise to the pipeline. In the near- to medium-future, we believe the company is likely to be able to update on: • The outcome of sub-licensed IP to Quark (partnered with Novartis) for QPI1002 (currently Phase 3), where SLN are eligible for c1-4% royalties or c15% of clinical/commercial milestone payments. • Developments in SLN’s pipeline for new and existing assets. The lead candidate SLN124 for beta-thalassaemia, with CTA planned for H1 2019).
soundbuy
10/12/2018
11:26
So suggested that it was Amicus that was looking at SLN. Does this clear the way and why they settled?
waterloo01
10/12/2018
11:16
Reactions a bit OTT. Guess many expecting a better outcome from trial. I'll stick around for a bit on hopes for take-over, now this is out the way. Quark results due shortly: QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT). Results due December 18
waterloo01
10/12/2018
10:25
News went down well then..............
soundbuy
10/12/2018
08:36
The grant of the licence for all other future Alnylam products presumably includes an undisclosed one off payment. "Terms of the settlement, which includes no admissions by any party, are otherwise confidential."
callumross
10/12/2018
08:34
It does look like a decent deal for Alny, less so for SLN but it does reinforce the patent and might lead to some corporate action?
waterloo01
10/12/2018
08:26
Looks to me like a pretty good outcome for Alny. Do others see it differently? "Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline). Such license is fully paid up with no milestones or royalties, except for the limited royalty on ONPATTRO net sales in the EU described above. " hTtp://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-settlement-litigation-silence-therapeutics
1gw
10/12/2018
07:46
If there's a potential acquirer out there this removes the uncertainty
soundbuy
10/12/2018
07:25
The mostly likely (and sensible) outcome.......
soundbuy
10/12/2018
07:23
So a deal done before the trial.
waterloo01
10/12/2018
07:19
Deal then, but with limits on geographic scope, duration and magnitude of royalty. Maybe some further value as a precedent for other potential drugs?
1gw
07/12/2018
16:37
So, settlement talks over the weekend, in court on Monday if no deal reached? Doesn't look like the market's expecting sln to come out on top.
1gw
04/12/2018
10:22
Hi Callumross,do you know what the "AMENDED COMPLAINT" judgement means.
tshirley12
03/12/2018
16:22
Alnylam are the plaintiff (or pursuer as we call it in Scotland!) in this case and SLN defended the case on grounds that there is no jurisdiction of the Court.
callumross
03/12/2018
15:34
If I read that correct Alnylam have failed to get it dismissed before the hearing. Makes one feel that a deal on the steps might be possible, but certainly doesn't help Alnylam case.
waterloo01
03/12/2018
15:27
Order on motion to dismiss Alnylam case for lack of jurisdiction; https://www.pacermonitor.com/public/case/24076996/Alnylam_Pharmaceuticals,_Inc_v_Silence_Therapeutics_GmbH_et_al
callumross
03/12/2018
15:27
Order on motion to dismiss Alnylam case for lack of jurisdiction; https://www.pacermonitor.com/public/case/24076996/Alnylam_Pharmaceuticals,_Inc_v_Silence_Therapeutics_GmbH_et_al
callumross
30/11/2018
14:47
Well, whatever the reason, nice to see an attempt at a bounce today. Court case due to start a week on Monday, so if they are going to settle before it starts, not a lot of time left now.
1gw
30/11/2018
10:14
Don't worry about the chart.In this case it's irrelevant.A big line of stock has finished.They sold indiscriminately into a falling market.Looking for a big bounce which has already started.
wantage
24/11/2018
13:33
Alny's latest 10-Q, filed on 7th November suggests we're still on for 10th December. "On December 10, 2018, the High Court will hear the claim brought against us by Silence alleging that ONPATTRO (patisiran) infringes the ‘547 patent, as amended in the United Kingdom, and will also hear our claim seeking a declaration of non-infringement by ONPATTRO and revocation of the ‘547 patent in its entirety. Silence is seeking monetary damages as well as a permanent injunction." Alny also say: "Although we believe Silence’s patents are invalid and not infringed by ONPATTRO or our current product candidates and that, therefore, Silence would not be entitled to the injunctive relief or monetary damages it seeks, litigation is subject to inherent uncertainty, and a court could ultimately rule against us." That uncertainty is felt on both sides of course, which is perhaps why a lot of cases are settled out of court.
1gw
24/11/2018
02:36
I’ll nab some if they go sub 70p
volsung
24/11/2018
02:32
You will be soon able to snap these up sub 70p according to Mr Chart It's a real bad one 70p gets bust and its the 2012 low next support https://uk.advfn.com/cmn/chrt/chrt_wrap.php?epic=LSE%3ASLN&name=&type=1&size=2&period=13&date1_day=27&date1_month=10&date1_year=2011&date2_day=24&date2_month=11&;date2_year=2018&;ind_type1=0&ind_type2=0&ind_type3=0 dyor that would be 40p in 2012 money https://uk.advfn.com/cmn/chrt/chrt_wrap.php?epic=LSE%3ASLN&name=&type=1&size=2&period=13&date1_day=27&date1_month=10&date1_year=2011&date2_day=24&date2_month=11&;date2_year=2012&;ind_type1=0&ind_type2=0&ind_type3=0
buywell3
23/11/2018
23:29
Can't see how the market is saying Court case lost when it hasn't even begun! I too have noticed the 1 and 2 share trades and wondered whether it is a form of market manipulation by0 a shorter. But on the broader picture it is an illiquid share (which works both ways) and the whole market has been depressed in the last 3 months, especially the tech sector and even more so if you are an AIM share like SLN. Could turn on a sixpence with a change in market sentiment generally or some positive SLN specific news.
callumross
23/11/2018
22:23
Can anybody help me understand what is going on with this share.I have bought and sold a few shares and commodities over the years,but I certainly don't have any great expertise.But watching this share going down on the back of 1 and 2 shares being sold is very strange.All the time the price going lower and lower on very low volume.Is the market saying the court case is lost and pricing the share accordingly,I really would appreciate any comments about what is going on.
tshirley12
Chat Pages: 2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  2013  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190626 06:13:02